

Princess Ghida Talal Opens Hikma's Annual Forum for the treatment of leukemia and other blood cancers

In Collaboration with the University of Texas MD Anderson Cancer Center

Amman, 18 April 2018 – HRH Princess Ghida Talal, the Chairperson of the King Hussein Cancer Foundation and Center in Amman, Jordan, opened the second 'Hikma Cancer Network - Middle East and North Africa Forum. The event was hosted by Hikma Pharmaceuticals PLC (**Hikma**, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the multinational generic pharmaceutical company, in collaboration with the University of Texas MD Anderson Cancer Center - Department of Leukemia.

The Forum was attended by Mr. Mazen Darwazah **Hikma** Executive Vice Chairman, President and CEO of MENA and Emerging Markets and Forum Chairperson Professor Hagop Kantarijan, Chairman of the Department of Leukemia at MD Anderson Cancer Centre, University of Texas.

The Forum, Held for the second consecutive year at the King Hussein Bin Talal Convention Centre, Dead Sea, Jordan, revolved around providing cancer specialists with cutting-edge knowledge in their fields. The two-day forum saw the participation of around 200 key opinion leaders and practicing physicians from across the Middle East and North Africa (MENA), in addition to 12 international speakers hailing from the U.S. MD Anderson Cancer Center and Europe. For the duration of the event, participants attended presentations on the most advanced treatments available for the management of different types of cancers, allowing them the opportunity to learn about the developments taking place in this niche medical field straight from the experts.

HRH Princess Ghida Talal said, "With every moment we hesitate, the incidence of cancer increases, so we must unite our efforts and fight it with all our force." And she went on to say, "I would like to thank Dr. Hagop Kantarijan, the eminent chair of the conference today for being here with us, and I thank **Hikma** for continuously fostering discussion and mobilising action against the most pressing health issues of our time."

On this occasion, Mazen Darwazah, **Hikma** Executive Vice Chairman, President and CEO of MENA and Emerging Markets, said, "We are delighted to be expanding on the success of last year's forum, in cooperation with the respected Department of Leukemia at University of Texas MD Anderson Cancer Center. This forum reflects our dedication to ensuring that medical professionals across the MENA region are sharing best medical practises and the latest in the field of cancer treatment,



which in turn, allows us to continue to pursue our mission of putting 'better health, within reach, every day'."

Forum Chairperson Professor Hagop Kantarijan, Chairman of the Department of Leukemia at MD Anderson Cancer Centre, University of Texas, said, "The purpose of this annual conference is to expand our knowledge and allow us to serve our patients better and to develop a solid infrastructure for cancer research in the MENA region."

- Ends-

About Hikma

Hikma puts better health, within reach, every day, for millions of people in more than 50 countries around the world. For 40 years, we have been creating high-quality medicines, and making them accessible and affordable to the people who need them. We are a global company with a local presence across the United States (U.S.), the Middle East and North Africa (MENA), and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We are committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com, or contact:

Hana Darwazeh Ramadan Email: Media@Hikma.com Tel: +962 6 580 2900

This press release has been distributed by Bidaya Corporate Communications on behalf of Hikma Pharmaceuticals.

For more information or assistance, please contact us at:



Tel: +962 6 585 4002/6 Fax: +962 6 585 3001

P.O. Box: 930391, Amman 11193, Jordan

Email: media@bidayacorp.com